Somnomed Limited (SOMNF) AI Stock Analysis

Somnomed Limited

(Other OTC:SOMNF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Cash Generation and Balance SheetPositive operating and free cash flow, combined with low leverage and a meaningful equity base, gives SomnoMed greater capacity to fund operations and growth internally. This strengthens financial resilience and reduces reliance on external financing over the next several quarters.

Negative Factors

Persistent Net Losses and Negative ROEDespite improved EBIT and EBITDA, SomnoMed remains loss-making at the net-income level and does not yet generate positive returns on shareholder capital. Continued below-the-line costs limit earnings quality and weaken the evidence that operational recovery is fully durable.

Somnomed Limited (SOMNF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $39.56M
Dividend Yield: ―
Average Volume (3M): 2,850
Price to Earnings (P/E): -24.0
Beta (1Y): 0.90
Revenue Growth: 7.53%
EPS Growth: 15.69%
Country: US
Employees: 300
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Somnomed Limited Business Overview & Revenue Model

Company Description

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent...

Somnomed Limited Earnings Call Summary

Earnings Call Date:Aug 26, 2026(Q4-2026)|% Change Since:-59.73%|Next Earnings Date:May 26, 2022

Earnings Call SentimentNeutral

The call highlights a solid financial and operational recovery with meaningful improvements in EBITDA (+19%), margin expansion, positive cash generation and manufacturing scale gains. North America showed clear growth leadership and early product innovation (Virtus) feedback is encouraging. However, material headwinds temper the outlook: weaker second-half performance, structural reimbursement and access issues in Europe, significant AUD appreciation weighing on reported results, APAC demand softness, a small negative free cash flow position due to investments, and regulatory/commercial uncertainty on the Connected Care (Rest Assure) roadmap. Management has set a cautious near-term guidance posture (targeting high single-digit revenue growth for FY'27 and maintaining FY'26 EBITDA margins) and plans further disclosure at the AGM.

Positive Updates

EBITDA Growth and Margin Expansion

EBITDA increased 19% year-on-year to $10.9 million and EBITDA margin improved to 9.6% (up from 8.2%), driven by higher revenue, improved gross margin and disciplined operating cost management.

Negative Updates

Second Half Revenue Weakness and Divergent Half-on-Half Performance

The business experienced a 'tale of two halves' — second half revenue declined 7% (reported) and was down less than 1% in constant currency, offsetting strong first-half growth and indicating uneven momentum across the year.

Company Guidance

Guidance: management is targeting high single‑digit revenue growth for FY'27 while keeping EBITDA margins broadly consistent with FY'26 (FY'26 revenue $114.5m; EBITDA $10.9m; EBITDA margin 9.6%), with more detailed guidance ranges to be provided at the AGM in November; longer‑term (FY'30) objectives are to return to double‑digit revenue growth and progressively expand EBITDA margins through scale and efficiency. Key assumptions and sensitivities cited include continued North America growth, stabilization of Europe, a successful global rollout and adoption of Virtus in H2 FY'27, maintaining stable margins while investing in product and Connected Care initiatives, and monitoring material FX movements (c.95% of revenues in non‑AUD currencies).

Somnomed Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SOMNF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:COH	63Neutral	AUD 9.39B	63.84	8.01%	2.40%	-0.90%	-62.14%
AU:CMP	58Neutral	AUD 47.94M	218.18	0.93%	―	18.54%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
AU:4DX	45Neutral	AUD 1.47B	-6.19	-288.42%	―	20.64%	-457.40%
AU:MX1	41Neutral	AUD 27.10M	-2.52	-188.06%	―	15.58%	37.17%
AU:CYC	36Underperform	AUD 53.44M	-2.66	-62.14%	―	12.05%	-31.71%

* General Sector Average

Performance Comparison

SOMNF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SOMNF	Somnomed Limited	0.18	-0.28	-61.04%
AU:COH	Cochlear Limited	143.64	-130.85	-47.67%
AU:CMP	Compumedics Limited	0.24	-0.08	-25.00%
AU:CYC	Cyclopharm Limited	0.42	-0.24	-35.61%
AU:MX1	Micro-X Ltd.	0.04	-0.08	-70.00%
AU:4DX	4DMedical Ltd	2.44	0.83	51.55%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Somnomed Limited AI Stock Analysis